Home
 /
Papers
 /
Cancer Biology
 /
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer
Preprint
Open access
Top 1% · Validated by QED

Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer

Jie Luo, Jianzhang Yang, Jean Ching-Yi Tien +23 more
April 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.04.24.720638
99
%
QED Score
QED Impressions

DALTACs establish that enforcing non-native domain interactions within endogenous complexes locks them in transcriptionally inert states—redefining induced proximity beyond degradation and delivering a lineage-selective, super-inhibitory attack on castration-resistant prostate cancer.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Domain-ALTeration Chimeras (DALTACs) represent a novel therapeutic modality that rewires oncogenic transcriptional complexes by enforcing non-native domain interactions between endogenous protein partners; the first-in-class AR–p300/CBP DALTAC-1 induces synthetic proximity between the AR ligand-binding domain and p300/CBP bromodomain, thereby reprogramming p300 substrate specificity to suppress enhancer-associated histone acetylation while inducing neomorphic acetylation of AR complex components, ultimately collapsing the AR neo-enhanceosome and achieving lineage-selective tumor regression in AR-positive prostate cancer models with superior efficacy compared to combined inhibition of individual components.

See full analysis
Main Claim 1 –

DALTAC-1 Inhibits Prostate Cancer Growth Better Than Dual Inhibitors

Supporting evidence

  • DALTAC-1 Engages AR and p300/CBP by Thermal Stabilization
Main Claim 2 –

DALTAC-1 Selectively Inhibits Proliferation in AR-Positive Prostate Cancer

Supporting evidence

  • DALTAC-1 Cytotoxicity Persists After Compound Washout
Main Claim 3 –

DALTAC-1 Forms Stable AR–p300 Ternary Complex Enhancing Interaction

Supporting evidence

  • Salt Bridges and Hydrogen Bonds Stabilize AR–p300–DALTAC-1 Complex
Main Claim 4 –

DALTAC-1 AR-Dependently Suppresses Enhancer Histone Acetylation Including H2BNTac

Supporting evidence

  • DALTAC-1 Decreases Histone Acetylation but Increases AR-Complex Acetylation
  • DALTAC-1 More Strongly Represses AR Transcription Than Dual Inhibitors

Abstract

Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer (mCRPC), where AR maintains oncogenic enhancer programs through dynamic, domain-specific interactions with the lysine acetyltransferases p300/CBP and associated cofactors. Here, we describe a mechanistically distinct therapeutic modality, Domain-ALTeration Chimeras (DALTACs), designed to rewire endogenous protein complexes by enforcing non-native domain–domain interactions rather than degrading or inhibiting individual components. Our first-in-class molecule, AR–p300/CBP DALTAC-1, induces a synthetic proximity between the AR ligand-binding domain and the p300/CBP bromodomain, thereby misconfiguring the native AR–p300/CBP interface and locking the complex into a non-productive, transcriptionally inert state. DALTAC-1 triggers a profound “super-inhibitory” effect, suppressing AR-driven transcription and proliferation more potently than combined AR and p300/CBP inhibition. Mechanistically, DALTAC-1 reprograms the substrate specificity of p300/CBP, extinguishing the enhancer-associated histone mark H2B N-terminal acetylation (H2BNTac) while inducing neomorphic acetylation of AR and SRC2/3, culminating in collapse of the AR neo-enhanceosome. Chromatin profiling revealed widespread redistribution of AR and p300 toward canonical palindromic AREs, coupled with attenuation of ERG/BRD4 recruitment and a near complete loss of histone H2BNTac acetylation and RNA polymerase II loading at oncogenic AR/ERG neo-enhancers. Strikingly, DALTAC-1 exhibits exquisite lineage selectivity, displaying potent activity in AR-positive prostate cancer cells and patient-derived organoids while sparing AR-negative or non-prostate lineages. In multiple in vivo models, including castration-resistant and patient-derived xenograft tumors, DALTAC-1 induces deep and durable tumor regressions with favorable tolerability. Together, these findings establish DALTACs as a broadly applicable strategy to rewire disease-defining protein complexes by altering their domain topology, expanding the conceptual and therapeutic landscape of induced proximity agents. The precision and lineage-selective action of DALTAC-1 highlight its strong translational potential for treating AR-driven prostate cancer.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?